1 4351 136 MIR-199A-5P SILENCING REGULATES THE UNFOLDED PROTEIN RESPONSE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ALPHA1-ANTITRYPSIN DEFICIENCY. RATIONALE: RETENTION OF ABNORMAL ALPHA1-ANTITRYPSIN (AAT) ACTIVATES THE UNFOLDED PROTEIN RESPONSE IN AAT-DEFICIENT MONOCYTES. THE REGULATORY ROLE OF MICRORNAS (MIRNAS) IN UNFOLDED PROTEIN RESPONSES AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATHOGENESIS HAS NOT BEEN INVESTIGATED. OBJECTIVES: TO INVESTIGATE MIRNA EXPRESSION AND FUNCTION IN MM AND ZZ MONOCYTES AND IDENTIFY MIRNA(S) REGULATING THE UNFOLDED PROTEIN RESPONSE. METHODS: PERIPHERAL BLOOD MONOCYTES WERE ISOLATED FROM ASYMPTOMATIC AND SYMPTOMATIC MM AND ZZ INDIVIDUALS FOR MIRNA EXPRESSION PROFILING AND PYROSEQUENCING ANALYSIS. MIRNA/GENE AND PROTEIN EXPRESSION WAS MEASURED WITH QUANTITATIVE POLYMERASE CHAIN REACTION AND WESTERN BLOTTING. OVEREXPRESSION AND INHIBITION STUDIES WERE PERFORMED WITH PRE-MIR OR ANTI-MIR, RESPECTIVELY. LUCIFERASE REPORTER GENES WERE USED TO ELUCIDATE DIRECT MIRNA-TARGET INTERACTIONS. INFLAMMATORY CYTOKINES WERE DETECTED USING THE MESO SCALE DISCOVERY PLEX ASSAYS. MEASUREMENTS AND MAIN RESULTS: FORTY-THREE MIRNAS WERE DIFFERENTIALLY EXPRESSED, WITH MIR-199A-5P MOST HIGHLY UP-REGULATED IN ASYMPTOMATIC ZZ VERSUS MM MONOCYTES. MIR-199A-2 PROMOTER HYPERMETHYLATION INHIBITS MIR-199A-5P EXPRESSION AND WAS INCREASED IN SYMPTOMATIC MM AND ZZ MONOCYTES COMPARED WITH ASYMPTOMATIC COUNTERPARTS. GRP78, ACTIVATING TRANSCRIPTION FACTOR 6, P50, AND P65 WERE INCREASED IN SYMPTOMATIC VERSUS ASYMPTOMATIC ZZ MONOCYTES. RECIPROCAL DOWN- OR UP-REGULATION OF THESE MARKERS WAS OBSERVED AFTER MIRNA MODULATION. DIRECT MIR-199A-5P TARGETING OF ACTIVATING TRANSCRIPTION FACTOR 6, P50, AND P65 BY MIR-199A-5P WAS DEMONSTRATED USING LUCIFERASE REPORTER SYSTEMS. OVEREXPRESSION OF MIR-199A-5P ALSO DECREASED OTHER ARMS OF THE UPR AND EXPRESSION OF CYTOKINES THAT ARE NOT PUTATIVE TARGETS. CONCLUSIONS: MIR-199A-5P IS A KEY REGULATOR OF THE UNFOLDED PROTEIN RESPONSE IN AAT-DEFICIENT MONOCYTES, AND EPIGENETIC SILENCING OF ITS EXPRESSION REGULATES THIS PROCESS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 2014 2 1859 28 EMBEDDING THE COMMUNITY AND INDIVIDUALS IN DISEASE PREVENTION. THE PRIMARY PREVENTION OF NON-COMMUNICABLE DISEASES IS ONE OF THE MOST CHALLENGING AND EXCITING ASPECTS OF MEDICINE AND PRIMARY CARE THIS CENTURY. FOR CANCER, IT IS AN URGENT MATTER IN LIGHT OF THE INCREASING BURDEN OF THE DISEASE AMONG YOUNGER PEOPLE AND THE HIGHER FREQUENCY OF MORE AGGRESSIVE FORMS OF THE DISEASE FOR ALL AGES. MOST CHRONIC DISORDERS RESULT FROM THE INFLUENCE OF THE ENVIRONMENT ON THE EXPRESSION OF GENES WITHIN AN INDIVIDUAL. THE ENVIRONMENT AT-LARGE ENCOMPASSES LIFESTYLE (INCLUDING NUTRITION), AND CHEMICAL/PHYSICAL AND SOCIAL EXPOSURES. IN CANCER, THE INTERACTION BETWEEN THE (EPI)GENETIC MAKEUP OF AN INDIVIDUAL AND A MULTIPLICITY OF ENVIRONMENTAL RISK AND PROTECTING FACTORS IS CONSIDERED KEY TO DISEASE ONSET. THUS, LIKE FOR PRECISION THERAPY DEVELOPED FOR PATIENTS, PERSONALIZED OR PRECISION PREVENTION IS ENVISIONED FOR INDIVIDUALS AT RISK. PREVENTION MEANS IDENTIFYING PEOPLE AT HIGHER RISK AND INTERVENING TO REDUCE THE RISK. IT REQUIRES BIOLOGICAL MARKERS OF RISK AND NON-AGGRESSIVE PREVENTIVE ACTIONS FOR THE INDIVIDUAL, BUT IT ALSO INVOLVES ACTING ON THE ENVIRONMENT AND THE COMMUNITY. SOCIAL SCIENTISTS ARE CONSIDERING MICRO (INDIVIDUAL/FAMILY), MESO (COMMUNITY), AND MACRO (COUNTRY POPULATION) LEVELS OF CARE TO ILLUSTRATE THAT PROBLEMS AND SOLUTIONS EXIST ON DIFFERENT SCALES. IDEALLY, THE DESIGN OF INTERVENTIONS IN PREVENTION SHOULD INTEGRATE ALL THESE LEVELS. IN THIS PERSPECTIVE ARTICLE, USING THE EXAMPLE OF BREAST CANCER, WE ARE DISCUSSING CHALLENGES AND POSSIBLE SOLUTIONS FOR A MULTIDISCIPLINARY COMMUNITY OF SCIENTISTS, PRIMARY HEALTH CARE PRACTITIONERS AND CITIZENS TO DEVELOP A HOLISTIC APPROACH OF PRIMARY PREVENTION, KEEPING IN MIND EQUITABLE ACCESS TO CARE. 2022 3 3199 39 HDAC1 INTERACTS WITH THE P50 NF-?B SUBUNIT VIA ITS NUCLEAR LOCALIZATION SEQUENCE TO CONSTRAIN INFLAMMATORY GENE EXPRESSION. THE NF-?B P50 SUBUNIT IS AN IMPORTANT REGULATOR OF INFLAMMATION, WITH RECENT EXPERIMENTAL EVIDENCE TO SUPPORT IT ALSO HAVING A TUMOR SUPPRESSOR ROLE. CLASSICALLY, P50 FUNCTIONS IN HETERODIMERIC FORM WITH THE RELA (P65) NF-?B SUBUNIT TO ACTIVATE INFLAMMATORY GENES. HOWEVER, P50 ALSO FORMS HOMODIMERS WHICH ACTIVELY REPRESS NF-?B-DEPENDENT INFLAMMATORY GENE EXPRESSION AND EXERT AN IMPORTANT BRAKE ON THE INFLAMMATORY PROCESS. THIS REPRESSIVE ACTIVITY OF P50:P50 IS THOUGHT TO BE IN PART MEDIATED BY AN INTERACTION WITH THE EPIGENETIC REPRESSOR PROTEIN HISTONE DEACETYLASE 1 (HDAC1). HOWEVER, NEITHER THE INTERACTION OF P50 WITH HDAC1 NOR THE REQUIREMENT OF HDAC1 FOR THE REPRESSIVE ACTIVITIES OF P50 HAS BEEN WELL DEFINED. HERE WE EMPLOYED IN SILICO PREDICTION WITH IN VITRO ASSAYS TO MAP SITES OF INTERACTION OF HDAC1 ON THE P50 PROTEIN. DIRECTED MUTAGENESIS OF ONE SUCH REGION RESULTED IN ALMOST COMPLETE LOSS OF HDAC1 BINDING TO P50. TRANSFECTED MUTANT P50 PROTEIN LACKING THE PUTATIVE HDAC1 DOCKING MOTIF RESULTED IN ENHANCED CYTOKINE AND CHEMOKINE EXPRESSION WHEN COMPARED WITH CELLS EXPRESSING A TRANSFECTED WILD TYPE P50. IN ADDITION, EXPRESSION OF THIS MUTANT P50 WAS ASSOCIATED WITH ENHANCED CHEMOATTRACTION OF NEUTROPHILS AND ACETYLATION OF KNOWN INFLAMMATORY GENES DEMONSTRATING THE LIKELY IMPORTANCE OF THE P50:HDAC1 INTERACTION FOR CONTROLLING INFLAMMATION. THESE NEW INSIGHTS PROVIDE AN ADVANCE ON CURRENT KNOWLEDGE OF THE MECHANISMS BY WHICH NF-?B-DEPENDENT GENE TRANSCRIPTION ARE REGULATED AND HIGHLIGHT THE POTENTIAL FOR MANIPULATION OF P50:HDAC1 INTERACTIONS TO BRING ABOUT EXPERIMENTAL MODULATION OF CHRONIC INFLAMMATION AND PATHOLOGIES ASSOCIATED WITH DYSREGULATED NEUTROPHIL ACCUMULATION AND ACTIVATION. 2018 4 537 26 ASYMPTOMATIC HYPERURICEMIA: IS IT REALLY ASYMPTOMATIC? PURPOSE OF REVIEW: HYPERURICEMIA IS HIGHLY PREVALENT, AFFECTING APPROXIMATELY 38 MILLION INDIVIDUALS IN THE UNITED STATES. HOWEVER, THE SIGNIFICANCE OF ASYMPTOMATIC HYPERURICEMIA - HYPERURICEMIA IN THE ABSENCE OF GOUT - CONTINUES TO BE DEBATED. RECENT FINDINGS: ASYMPTOMATIC HYPERURICEMIA RESULTS IN MONOSODIUM URATE CRYSTAL DEPOSITION IN TISSUES, WHICH MAY PROMOTE CHRONIC INFLAMMATION. INTRACELLULARLY, HYPERURICEMIA INHIBITS THE MASTER REGULATOR ADENOSINE MONOPHOSPHATE (AMP)-ASSOCIATED PROTEIN KINASE AND MAY CONDITION INNATE IMMUNE RESPONSES THROUGH DURABLE EPIGENETIC MODIFICATIONS. AT THE POPULATION LEVEL, ASYMPTOMATIC HYPERURICEMIA IS ASSOCIATED WITH MULTIPLE COMORBIDITIES, INCLUDING HYPERTENSION, CHRONIC KIDNEY DISEASE, CORONARY ARTERY DISEASE, AND DIABETES; LIMITATIONS OF THESE STUDIES INCLUDE THAT MOST ARE RETROSPECTIVE AND SOME DO NOT RIGOROUSLY DISTINGUISH BETWEEN ASYMPTOMATIC HYPERURICEMIA AND GOUT. TREATMENT STUDIES SUGGEST THAT URATE LOWERING MAY REDUCE THE RISK OF INCIDENCE OR PROGRESSION OF SOME OF THESE COMORBIDITIES; UNFORTUNATELY, MANY OF THESE TREATMENT STUDIES ARE SMALL OR FLAWED, AND NOT ALL STUDY RESULTS ARE CONSISTENT. SUMMARY: ACCUMULATING EVIDENCE SUGGESTS THAT ASYMPTOMATIC HYPERURICEMIA CONTRIBUTES TO THE COMORBIDITIES WITH WHICH IT ASSOCIATES AND THAT PROPER ASYMPTOMATIC HYPERURICEMIA TREATMENT MAY REDUCE FUTURE RISK. ADDITIONAL PROSPECTIVE TRIALS ARE NEEDED TO DEFINITELY ESTABLISH CAUSALITY AND SUPPORT DECISION-MAKING AS TO WHETHER, AND WHICH PATIENTS WITH ASYMPTOMATIC HYPERURICEMIA WOULD WARRANT URATE-LOWERING TREATMENT. 2020 5 4305 37 MICRORNA-27A-3P ENHANCES THE INFLAMMATORY PHENOTYPE OF JUVENILE IDIOPATHIC ARTHRITIS FIBROBLAST-LIKE SYNOVIOCYTES. BACKGROUND: JUVENILE IDIOPATHIC ARTHRITIS (JIA) IS THE MOST PREVALENT CHRONIC PEDIATRIC RHEUMATIC DISORDER. IN JOINTS OF JIA PATIENTS, AGGRESSIVE PHENOTYPIC CHANGES IN FIBROBLAST-LIKE SYNOVIOCYTES (FLS) OF THE SYNOVIAL LINING PLAY A KEY ROLE IN INFLAMMATION. MICRORNAS ARE DYSREGULATED IN RHEUMATOID ARTHRITIS AND JIA, INCLUDING MIR-27A-3P. HOWEVER, IT IS NOT UNDERSTOOD IF MIR-27A-3P, ENRICHED IN JIA SYNOVIAL FLUID (SF) AND LEUKOCYTES, ALTERS FLS FUNCTION. METHODS: PRIMARY JIA FLS CELLS WERE TRANSFECTED WITH A MIR-27A-3P MIMIC OR A NEGATIVE CONTROL MICRORNA (MIR-NC) AND STIMULATED WITH POOLED JIA SF OR INFLAMMATORY CYTOKINES. VIABILITY AND APOPTOSIS WERE ANALYZED BY FLOW CYTOMETRY. PROLIFERATION WAS EVALUATED USING A (3)H-THYMIDINE INCORPORATION ASSAY. CYTOKINE PRODUCTION WAS ASSESSED BY QPCR AND ELISA. EXPRESSION OF TGF-BETA PATHWAY GENES WAS DETERMINED USING A QPCR ARRAY. RESULTS: MIR-27A-3P WAS CONSTITUTIVELY EXPRESSED IN FLS. OVEREXPRESSION OF MIR-27A-3P CAUSED INCREASED INTERLEUKIN-8 SECRETION IN RESTING FLS, AND INTERLEUKIN-6 WAS ELEVATED IN SF-ACTIVATED FLS COMPARED TO MIR-NC. FURTHERMORE, STIMULATION WITH PRO-INFLAMMATORY CYTOKINES AUGMENTED FLS PROLIFERATION IN MIR-27A-3P-TRANSFECTED FLS RELATIVE TO MIR-NC. EXPRESSION OF MULTIPLE TGF-BETA PATHWAY GENES WAS MODULATED BY OVEREXPRESSION OF MIR-27A-3P. CONCLUSIONS: MIR-27A-3P SIGNIFICANTLY CONTRIBUTES TO FLS PROLIFERATION AND CYTOKINE PRODUCTION, MAKING IT A POTENTIAL CANDIDATE FOR EPIGENETIC THERAPY THAT TARGETS FLS IN ARTHRITIS. 2023 6 4515 27 MULTI-OMICS APPROACHES FOR PRECISION OBESITY MANAGEMENT : POTENTIALS AND LIMITATIONS OF OMICS IN PRECISION PREVENTION, TREATMENT AND RISK REDUCTION OF OBESITY. INTRODUCTION: OBESITY IS A MULTIFACTORIAL CHRONIC DISEASE THAT CANNOT BE ADDRESSED BY SIMPLY PROMOTING BETTER DIETS AND MORE PHYSICAL ACTIVITY. TO DATE, NOT A SINGLE COUNTRY HAS SUCCESSFULLY BEEN ABLE TO CURB THE ACCUMULATING BURDEN OF OBESITY. ONE EXPLANATION FOR THE LACK OF PROGRESS IS THAT LIFESTYLE INTERVENTION PROGRAMS ARE TRADITIONALLY IMPLEMENTED WITHOUT A COMPREHENSIVE EVALUATION OF AN INDIVIDUAL'S DIAGNOSTIC BIOMARKERS. EVIDENCE FROM GENOME-WIDE ASSOCIATION STUDIES HIGHLIGHT THE IMPORTANCE OF GENETIC AND EPIGENETIC FACTORS IN THE DEVELOPMENT OF OBESITY AND HOW THEY IN TURN AFFECT THE TRANSCRIPTOME, METABOLITES, MICROBIOMES, AND PROTEOMES. OBJECTIVE: THE PURPOSE OF THIS REVIEW IS TO PROVIDE AN OVERVIEW OF THE DIFFERENT TYPES OF OMICS DATA: GENOMICS, EPIGENOMICS, TRANSCRIPTOMICS, PROTEOMICS, METABOLOMICS AND ILLUSTRATE HOW A MULTI-OMICS APPROACH CAN BE FUNDAMENTAL FOR THE IMPLEMENTATION OF PRECISION OBESITY MANAGEMENT. RESULTS: THE DIFFERENT TYPES OF OMICS DESIGNS ARE GROUPED INTO TWO CATEGORIES, THE GENOTYPE APPROACH AND THE PHENOTYPE APPROACH. WHEN APPLIED TO OBESITY PREVENTION AND MANAGEMENT, EACH OMICS TYPE COULD POTENTIALLY HELP TO DETECT SPECIFIC BIOMARKERS IN PEOPLE WITH RISK PROFILES AND GUIDE HEALTHCARE PROFESSIONALS AND DECISION MAKERS IN DEVELOPING INDIVIDUALIZED TREATMENT PLANS ACCORDING TO THE NEEDS OF THE INDIVIDUAL BEFORE THE ONSET OF OBESITY. CONCLUSION: INTEGRATING MULTI-OMICS APPROACHES WILL ENABLE A PARADIGM SHIFT FROM THE ONE SIZE FITS ALL APPROACH TOWARDS PRECISION OBESITY MANAGEMENT, I.E. (1) PRECISION PREVENTION OF THE ONSET OF OBESITY, (2) PRECISION MEDICINE AND TAILORED TREATMENT OF OBESITY, AND (3) PRECISION RISK REDUCTION AND PREVENTION OF SECONDARY DISEASES RELATED TO OBESITY. 2023 7 4304 30 MICRORNA-223 PROTECTS NEURONS FROM DEGENERATION IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS. MULTIPLE SCLEROSIS IS A CHRONIC INFLAMMATORY, DEMYELINATING, AND NEURODEGENERATIVE DISEASE AFFECTING THE BRAIN, SPINAL CORD AND OPTIC NERVES. NEURONAL DAMAGE IS TRIGGERED BY VARIOUS HARMFUL FACTORS THAT ENGAGE DIVERSE SIGNALLING CASCADES IN NEURONS; THUS, THERAPEUTIC APPROACHES TO PROTECT NEURONS WILL NEED TO FOCUS ON AGENTS THAT CAN TARGET MULTIPLE BIOLOGICAL PROCESSES. WE HAVE THEREFORE FOCUSED OUR ATTENTION ON MICRORNAS: SMALL NON-CODING RNAS THAT PRIMARILY FUNCTION AS POST-TRANSCRIPTIONAL REGULATORS THAT TARGET MESSENGER RNAS AND REPRESS THEIR TRANSLATION INTO PROTEINS. A SINGLE MICRORNA CAN TARGET MANY FUNCTIONALLY RELATED MESSENGER RNAS MAKING MICRORNAS POWERFUL EPIGENETIC REGULATORS. DYSREGULATION OF MICRORNAS HAS BEEN DESCRIBED IN MANY NEURODEGENERATIVE DISEASES INCLUDING MULTIPLE SCLEROSIS. HERE, WE REPORT THAT TWO MICRORNAS, MIR-223-3P AND MIR-27A-3P, ARE UPREGULATED IN NEURONS IN THE EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS MOUSE MODEL OF CNS INFLAMMATION AND IN GREY MATTER-CONTAINING MULTIPLE SCLEROSIS LESIONS. PRIOR WORK HAS SHOWN PERIPHERAL BLOOD MONONUCLEAR CELL CONDITIONED MEDIA CAUSES SUBLETHAL DEGENERATION OF NEURONS IN CULTURE. WE FIND OVEREXPRESSION OF MIR-27A-3P OR MIR-223-3P PROTECTS DISSOCIATED CORTICAL NEURONS FROM CONDITION MEDIA MEDIATED DEGENERATION. INTRODUCTION OF MIR-223-3P IN VIVO IN MOUSE RETINAL GANGLION CELLS PROTECTS THEIR AXONS FROM DEGENERATION IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS. IN SILICO ANALYSIS REVEALED THAT MESSENGER RNAS INVOLVED IN GLUTAMATE RECEPTOR SIGNALLING ARE ENRICHED AS MIR-27A-3P AND MIR-223-3P TARGETS. WE OBSERVE THAT ANTAGONISM OF NMDA AND AMPA TYPE GLUTAMATE RECEPTORS PROTECTS NEURONS FROM CONDITION MEDIA DEPENDENT DEGENERATION. OUR RESULTS SUGGEST THAT MIR-223-3P AND MIR-27A-3P ARE UPREGULATED IN RESPONSE TO INFLAMMATION TO MEDIATE A COMPENSATORY NEUROPROTECTIVE GENE EXPRESSION PROGRAM THAT DESENSITIZES NEURONS TO GLUTAMATE BY TARGETING MESSENGER RNAS INVOLVED IN GLUTAMATE RECEPTOR SIGNALLING. 2019 8 3797 15 INTERNATIONAL BREAST CANCER AND NUTRITION: A MODEL FOR RESEARCH, TRAINING AND POLICY IN DIET, EPIGENETICS, AND CHRONIC DISEASE PREVENTION. THIS ARTICLE SUMMARIZES PRESENTATIONS FROM THE INTERNATIONAL BREAST CANCER AND NUTRITION WORKSHOP HELD DURING THE ASN SCIENTIFIC SESSIONS AND ANNUAL MEETING AT EXPERIMENTAL BIOLOGY 2014 IN SAN DIEGO, CA, ON 28 APRIL 2014. AN INTERNATIONAL COLLABORATION WAS DESCRIBED AMONG TEAMS FROM LOW-, MIDDLE-, AND HIGH-INCOME COUNTRIES ADDRESSING ENVIRONMENTAL FACTORS, ESPECIALLY DIET, AND EPIGENETIC INTERACTIONS THAT AFFECT THE RISK OF CHRONIC DISEASE. SPEAKERS ADDRESSED OPPORTUNITIES AND CHALLENGES INVOLVED IN THIS TYPE OF INTERNATIONAL COLLABORATION, ASSESSING DIET AND NUTRITIONAL STATUS ACROSS A WIDE RANGE OF CULTURES, AND RESEARCH TOOLS AND DISCOVERIES FROM THIS GROUP. 2014 9 3769 18 INTEGRATIVE MEDICINE TO TACKLE THE PROBLEM OF CHRONIC DISEASES. THIS ARTICLE SUMMARIZES IMPORTANT WAYS THAT INTEGRATIVE MEDICINE CAN CONTRIBUTE TO RESOLVING THE GLOBAL HEALTH CRISIS WITH SPECIAL REFERENCE TO THE US. RESEARCH USING MODERN METHODS OF ANALYSIS OF CELLULAR CHANGES AT THE EPIGENETIC LEVEL HAS SHOWN THAT DIET AND LIFESTYLE INTERVENTIONS GREATLY IMPROVE THE STATE OF PATIENTS' HEALTH. ESTIMATES HAVE BEEN GIVEN THAT UP TO 75% OF ALL US HEALTH COSTS CAN BE SAVED BY THESE METHODS, PARTICULARLY IF APPLIED PREVENTATIVELY. IT IS THUS VITAL THAT ACTIVE STEPS ARE TAKEN TO IMPLEMENT SUCH PROGRAMS, TO REDUCE COSTS TO CITIZENS AND SOCIETY ALIKE, AS WELL AS TO GOVERNMENT. 2010 10 5743 32 SMOKING SUPPRESSES THE THERAPEUTIC POTENTIAL OF ADIPOSE STEM CELLS IN CROHN'S DISEASE PATIENTS THROUGH EPIGENETIC CHANGES. PATIENTS WITH CROHN'S DISEASE (CD) WHO SMOKE ARE KNOWN TO HAVE A WORSE PROGNOSIS THAN NEVER-SMOKERS AND A HIGHER RISK FOR POST-SURGICAL RECURRENCE, WHEREAS PATIENTS WHO QUIT SMOKING AFTER SURGERY HAVE SIGNIFICANTLY LOWER POST-OPERATIVE RECURRENCE. THE HYPOTHESIS WAS THAT SMOKING INDUCES EPIGENETIC CHANGES THAT IMPAIR THE CAPACITY OF ADIPOSE STEM CELLS (ASCS) TO SUPPRESS THE IMMUNE SYSTEM. IT WAS ALSO QUESTIONED WHETHER THIS IMPAIRMENT REMAINS IN EX-SMOKERS WITH CD. ASCS WERE ISOLATED FROM NON-SMOKERS, SMOKERS AND EX-SMOKERS WITH CD AND THEIR INTERACTIONS WITH IMMUNE CELLS WERE STUDIED. THE ASCS FROM BOTH SMOKERS AND EX-SMOKERS PROMOTED MACROPHAGE POLARIZATION TO AN M1 PRO-INFLAMMATORY PHENOTYPE, WERE NOT ABLE TO INHIBIT T- AND B-CELL PROLIFERATION IN VITRO AND ENHANCED THE GENE AND PROTEIN EXPRESSION OF INFLAMMATORY MARKERS INCLUDING INTERLEUKIN-1B. GENOME-WIDE EPIGENETIC ANALYSIS USING TWO DIFFERENT BIOINFORMATIC APPROACHES REVEALED SIGNIFICANT CHANGES IN THE METHYLATION PATTERNS OF GENES THAT ARE CRITICAL FOR WOUND HEALING, IMMUNE AND METABOLIC RESPONSE AND P53-MEDIATED DNA DAMAGE RESPONSE IN ASCS FROM SMOKERS AND EX-SMOKERS WITH CD. IN CONCLUSION, CIGARETTE SMOKING INDUCES A PRO-INFLAMMATORY EPIGENETIC SIGNATURE IN ASCS THAT LIKELY COMPROMISES THEIR THERAPEUTIC POTENTIAL. 2023 11 3853 26 IS MIR-223 UPREGULATION IN INFLAMMATORY BOWEL DISEASES A PROTECTIVE RESPONSE? INFLAMMATORY BOWEL DISEASES (IBD) ARE CHARACTERIZED BY CHRONIC INFLAMMATION AND DAMAGE OF COLONOCYTES WITH ETIOLOGY OF GENETIC, EPIGENETIC AND ENVIRONMENTAL FACTORS. MICRORNA-223 (MIR-223) HAS BEEN FOUND TO BE INCREASED IN BOTH IBD PATIENTS AND ANIMAL COLITIS MODELS. HOWEVER, CONTENTIOUS OPINIONS RELEVANT TO THE ROLES OF MIR-223 IN IBD HAVE BEEN REPORTED. NOTWITHSTADING THAT MOST STUDIES HAVE DESCRIBED THAT MIR-223 HAS ANTI-INFLAMMATORY EFFECTS, SEVERAL REPORTS HAVE PROGRESSED A PRO-INFLAMMATORY VIEW. IN THIS REVIEW, WE SUMMARISE BOTH THE ANTI-INFLAMMATORY AND PRO-INFLAMMATORY EFFECTS OF MIR-223 ON KEY MOLECULES IN INFLAMMATORY RESPONSES IN BOTH ANIMAL MODELS AND IN PATIENTS DIAGNOSED WITH IBD AND OBJECTIVELY DISCUSS THE POSSIBLE BASIS FOR THE DISCREPANCIES. 2023 12 3630 25 INCLUSION OF SOCIAL AND STRUCTURAL DETERMINANTS OF HEALTH TO ADVANCE UNDERSTANDING OF THEIR INFLUENCE ON THE BIOLOGY OF CHRONIC DISEASE. SOCIAL DETERMINANTS OF HEALTH (SDOH) CONSIDER SOCIAL, POLITICAL, AND ECONOMIC FACTORS THAT CONTRIBUTE TO HEALTH DISPARITIES IN PATIENTS AND POPULATIONS. THE MOST COMMON HEALTH-RELATED SDOH EXPOSURES ARE FOOD AND HOUSING INSECURITY, FINANCIAL INSTABILITY, TRANSPORTATION NEEDS, LOW LEVELS OF EDUCATION, AND PSYCHOSOCIAL STRESS. THESE DOMAINS DESCRIBE RISKS THAT CAN IMPACT HEALTH OUTCOMES MORE THAN HEALTH CARE. EPIDEMIOLOGIC AND TRANSLATIONAL RESEARCH DEMONSTRATES THAT SDOH FACTORS REPRESENT EXPOSURES THAT PREDICT HARM AND IMPACT THE HEALTH OF INDIVIDUALS. INTERNATIONAL AND NATIONAL GUIDELINES URGE HEALTH PROFESSIONALS TO ADDRESS SDOH IN CLINICAL PRACTICE AND PUBLIC HEALTH. THE FURTHER IMPLEMENTATION OF THESE RECOMMENDATIONS INTO BASIC AND TRANSLATIONAL RESEARCH, HOWEVER, IS LAGGING. HEREIN, WE CONSIDER A PRECISION HEALTH FRAMEWORK TO DESCRIBE HOW SDOH CONTRIBUTES TO THE EXPOSOME AND EXACERBATES PHYSIOLOGIC PATHWAYS THAT LEAD TO CHRONIC DISEASE. SDOH FACTORS ARE ASSOCIATED WITH VARIOUS FORMS OF STRESSORS THAT IMPACT PHYSIOLOGICAL PROCESSES THROUGH EPIGENETIC, INFLAMMATORY, AND REDOX REGULATION. MANY SDOH EXPOSURES MAY ADD TO OR POTENTIATE THE PATHOLOGIC EFFECTS OF ADDITIONAL ENVIRONMENTAL EXPOSURES. THIS OVERVIEW AIMS TO INFORM BASIC LIFE SCIENCE AND TRANSLATIONAL RESEARCHERS ABOUT SDOH EXPOSURES THAT CAN CONFOUND ASSOCIATIONS BETWEEN CLASSIC BIOMEDICAL DETERMINANTS OF DISEASE AND HEALTH OUTCOMES. TO ADVANCE THE STUDY OF TOXICOLOGY THROUGH EITHER QUALITATIVE OR QUANTITATIVE ASSESSMENT OF EXPOSURES TO CHEMICAL AND BIOLOGICAL SUBSTANCES, A MORE COMPLETE ENVIRONMENTAL EVALUATION SHOULD INCLUDE SDOH EXPOSURES. WE DISCUSS COMMON APPROACHES TO MEASURE SDOH FACTORS AT INDIVIDUAL AND POPULATION LEVELS AND REVIEW THE ASSOCIATIONS BETWEEN SDOH RISK FACTORS AND PHYSIOLOGIC MECHANISMS THAT INFLUENCE CHRONIC DISEASE. WE PROVIDE CLINICAL AND POLICY-BASED MOTIVATION TO ENCOURAGE RESEARCHERS TO CONSIDER THE IMPACT OF SDOH EXPOSURES ON STUDY RESULTS AND DATA INTERPRETATION. WITH VALID MEASURES OF SDOH FACTORS INCORPORATED INTO STUDY DESIGN AND ANALYSES, FUTURE TOXICOLOGICAL RESEARCH MAY CONTRIBUTE TO AN EVIDENCE BASE THAT CAN BETTER INFORM PREVENTION AND TREATMENT OPTIONS, TO IMPROVE EQUITABLE CLINICAL CARE AND POPULATION HEALTH. (C) 2022 WILEY PERIODICALS LLC. 2022 13 4371 34 MIRNAS POTENTIALLY INVOLVED IN POST LUNG TRANSPLANT-OBLITERATIVE BRONCHIOLITIS: THE ROLE OF MIR-21-5P. EPIGENETIC CHANGES, INCLUDING MIRNAS DEREGULATION, HAVE BEEN SUGGESTED TO PLAY A SIGNIFICANT ROLE IN DEVELOPMENT OF OBLITERATIVE BRONCHIOLITIS (OB) IN TRANSPLANTED LUNGS. MANY STUDIES HAVE TRIED TO IDENTIFY IDEAL CANDIDATE MIRNAS AND THE DOWNSTREAM PATHWAYS IMPLICATED IN THE BRONCHIOLAR FIBRO-OBLITERATIVE PROCESS. SEVERAL CANDIDATE MIRNAS, PREVIOUSLY INDICATED AS POSSIBLY BEING ASSOCIATED WITH OB, WERE ANALYZED BY COMBINING THE QUANTITATIVE REAL TIME-POLYMERASE CHAIN REACTION (QRT-PCR) AND IN SITU HYBRIDIZATION (ISH) OF LUNG TISSUES OF OB AFFECTED PATIENTS. DISEASE AND OB-LESION-SPECIFIC EXPRESSION OF MIR-21-5P WAS CONFIRMED AND BY COMPUTATIONAL ANALYSIS WE WERE ABLE TO IDENTIFY THE NETWORK OF GENES MOST PROBABLY ASSOCIATED MIR-21-5P IN THE CONTEXT OF OB FIBROGENESIS. AMONG ALL POTENTIALLY ASSOCIATED GENES, STAT3 HAD A VERY HIGH PROBABILITY SCORE. IMMUNOHISTOCHEMISTRY SHOWED THAT STAT3/MIR-21-5P WERE CO-OVER EXPRESSED IN OB LESIONS, THUS, SUGGESTING MIR-21-5P COULD REGULATE STAT3 EXPRESSION. HOWEVER, MIR-21-5P INHIBITION IN CULTURES OF BRONCHIOLITIS OBLITERANS SYNDROME (BOS) DERIVED MYOFIBROBLASTS DID NOT SIGNIFICANTLY AFFECT STAT3 MRNA AND PROTEIN EXPRESSION LEVELS. THIS STUDY DEMONSTRATES THE SPECIFICITY OF MIR-21-5P OVER-EXPRESSION IN OB LESIONS AND CONTRIBUTES TO EXISTING KNOWLEDGE ON THE MIR-21-5P DOWNSTREAM PATHWAY. ACTIVATION OF STAT3 IS ASSOCIATED WITH MIR-21-5P UPREGULATION, HOWEVER, STAT-3 NETWORK ACTIVATION IS MOST LIKELY COMPLEX AND MIR-21-5P IS NOT THE SOLE REGULATOR OF STAT3. 2021 14 5025 23 PERSONALIZED MANAGEMENT OF CARDIOVASCULAR DISORDERS. PERSONALIZED MANAGEMENT OF CARDIOVASCULAR DISORDERS (CVD), ALSO REFERRED TO AS PERSONALIZED OR PRECISION CARDIOLOGY IN ACCORDANCE WITH GENERAL PRINCIPLES OF PERSONALIZED MEDICINE, IS SELECTION OF THE BEST TREATMENT FOR AN INDIVIDUAL PATIENT. IT INVOLVES THE INTEGRATION OF VARIOUS "OMICS" TECHNOLOGIES SUCH AS GENOMICS AND PROTEOMICS AS WELL AS OTHER NEW TECHNOLOGIES SUCH AS NANOBIOTECHNOLOGY. MOLECULAR DIAGNOSTICS AND BIOMARKERS ARE IMPORTANT FOR LINKING DIAGNOSIS WITH THERAPY AND MONITORING THERAPY. BECAUSE CVD INVOLVE PERTURBATIONS OF LARGE COMPLEX BIOLOGICAL NETWORKS, A SYSTEMS BIOLOGY APPROACH TO CVD RISK STRATIFICATION MAY BE USED FOR IMPROVING RISK-ESTIMATING ALGORITHMS, AND MODELING OF PERSONALIZED BENEFIT OF TREATMENT MAY BE HELPFUL FOR GUIDING THE CHOICE OF INTERVENTION. BIOINFORMATICS TOOLS ARE HELPFUL IN ANALYZING AND INTEGRATING LARGE AMOUNTS OF DATA FROM VARIOUS SOURCES. PERSONALIZED THERAPY IS CONSIDERED DURING DRUG DEVELOPMENT, INCLUDING METHODS OF TARGETED DRUG DELIVERY AND CLINICAL TRIALS. INDIVIDUALIZED RECOMMENDATIONS CONSIDER MULTIPLE FACTORS - GENETIC AS WELL AS EPIGENETIC - FOR PATIENTS' RISK OF HEART DISEASE. EXAMPLES OF PERSONALIZED TREATMENT ARE THOSE OF CHRONIC MYOCARDIAL ISCHEMIA, HEART FAILURE, AND HYPERTENSION. SIMILAR APPROACHES CAN BE USED FOR THE MANAGEMENT OF ATRIAL FIBRILLATION AND HYPERCHOLESTEROLEMIA, AS WELL AS THE USE OF ANTICOAGULANTS. PERSONALIZED MANAGEMENT INCLUDES PHARMACOTHERAPY, SURGERY, LIFESTYLE MODIFICATIONS, AND COMBINATIONS THEREOF. FURTHER PROGRESS IN UNDERSTANDING THE PATHOMECHANISM OF COMPLEX CARDIOVASCULAR DISEASES AND IDENTIFICATION OF CAUSATIVE FACTORS AT THE INDIVIDUAL PATIENT LEVEL WILL PROVIDE OPPORTUNITIES FOR THE DEVELOPMENT OF PERSONALIZED CARDIOLOGY. APPLICATION OF PRINCIPLES OF PERSONALIZED MEDICINE WILL IMPROVE THE CARE OF THE PATIENTS WITH CVD. 2017 15 1294 42 DECREASED EXPRESSION OF MIR-20A AND MIR-92A IN THE SERUM FROM SULFUR MUSTARD-EXPOSED PATIENTS DURING THE CHRONIC PHASE OF RESULTING ILLNESS. CONTEXT: SULFUR MUSTARD (SM), WITH EXTENSIVE NUCLEOPHILIC AND ALKYLATING PROPERTIES, WAS EMPLOYED DURING THE IRAN-IRAQ WAR BY IRAQI FORCES. THE MOST CRITICAL COMPLICATIONS ATTRIBUTED TO SM ARE RELATED TO DANGEROUS PULMONARY DISORDERS COLLECTIVELY KNOWN AS "MUSTARD LUNG". THE SYMPTOMS GRADUALLY EMERGE OVER A LONG PERIOD, BECOMING CHRONIC, AND ARE DEPENDENT ON TIME AND THE AMOUNT OF EXPOSED SM. BECAUSE OF THE UNKNOWN AND COMPLEX NATURE OF THE DISEASE, NO DIFFERENTIAL DIAGNOSTIC METHOD OR ABSOLUTE TREATMENT STRATEGY HAS BEEN FORMALLY DEVELOPED. OBJECTIVE: THE AIM OF OUR STUDY WAS TO DETERMINE THE EXPRESSION PATTERN OF THE MICRORNAS (MIRNAS) MIR-92A AND MIR-20A IN THE SERUM OF PATIENTS WITH MUSTARD LUNG ALONG WITH THAT OF NORMAL INDIVIDUALS. MIRNAS HAVE BEEN SHOWN TO POSSESS STABLE PERSISTENCE IN BIOFLUIDS LIKE PLASMA AND SERUM AND ARE CONSIDERED NON-AGGRESSIVE BIOMARKERS HELPFUL FOR DIAGNOSIS AND TREATMENT OF MANY DISEASES. MATERIALS AND METHODS: A HIGHLY SENSITIVE APPROACH CALLED STEM-LOOP REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION WAS EMPLOYED TO STUDY THE EXPRESSION OF MIRNAS. RESULTS: THE EXPRESSION OF MIR-92A AND MIR-20A WAS SIGNIFICANTLY DOWN-REGULATED IN THE SERUM OF PATIENTS WITH MUSTARD LUNG COMPARED TO THE CONTROL GROUP. DISCUSSION: DOWN-REGULATION OF MIR-92A AND MIR-20A MAY BE DUE TO CHRONIC EPIGENETIC ALTERATIONS AFTER SM EXPOSURE, WHICH FINALLY LEADS TO CHANGES IN VITAL CELLULAR PROCESSES SUCH AS DIFFERENTIATION, PROLIFERATION AND SO FORTH. CONCLUSION: OUR FINDINGS MAY PROVIDE A DIFFERENTIAL DIAGNOSTIC METHOD THAT IS EFFECTIVE FOR DIAGNOSING LUNG DISEASES CAUSED BY SM EXPOSURE. ADDITIONALLY, THESE MIRNAS MAY BE REGARDED AS PROBABLE TARGETS FOR TREATMENT OF LUNG INJURIES. 2015 16 103 28 A REHABILOMICS FRAMEWORK FOR PERSONALIZED AND TRANSLATIONAL REHABILITATION RESEARCH AND CARE FOR INDIVIDUALS WITH DISABILITIES: PERSPECTIVES AND CONSIDERATIONS FOR SPINAL CORD INJURY. DESPITE MANY PEOPLE HAVING SIMILAR CLINICAL PRESENTATION, DEMOGRAPHIC FACTORS, AND CLINICAL CARE, OUTCOME CAN DIFFER FOR THOSE SUSTAINING SIGNIFICANT INJURY SUCH AS SPINAL CORD INJURY (SCI) AND TRAUMATIC BRAIN INJURY (TBI). IN ADDITION TO TRADITIONAL DEMOGRAPHIC, SOCIAL, AND CLINICAL FACTORS, VARIABILITY ALSO MAY BE ATTRIBUTABLE TO INNATE (INCLUDING GENETIC, TRANSCRIPTOMIC PROTEOMIC, EPIGENETIC) BIOLOGICAL VARIATION THAT INDIVIDUALS BRING TO RECOVERY AND THEIR UNIQUE RESPONSE TO THEIR CARE AND ENVIRONMENT. TECHNOLOGIES COLLECTIVELY CALLED "-OMICS" ENABLE SIMULTANEOUS MEASUREMENT OF AN ENORMOUS NUMBER OF BIOMOLECULES THAT CAN CAPTURE MANY POTENTIAL BIOLOGICAL CONTRIBUTORS TO HETEROGENEITY OF INJURY/DISEASE COURSE AND OUTCOME. DUE TO THE NATURE OF INJURY AND COMPLEX DISEASE, AND ITS ASSOCIATIONS WITH IMPAIRMENT, DISABILITY, AND RECOVERY, REHABILITATION DOES NOT LEND ITSELF TO A SINGULAR "PROTOCOLIZED" PLAN OF THERAPY. YET, BY NATURE AND BY NECESSITY, REHABILITATION MEDICINE OPERATES AS A FUNCTIONAL MODEL OF "PERSONALIZED CARE". THUS, THE CHALLENGE FOR SUCCESSFUL PROGRAMS OF TRANSLATIONAL REHABILITATION CARE AND RESEARCH IS TO IDENTIFY VIABLE APPROACHES TO EXAMINE BROAD POPULATIONS, WITH VARIED IMPAIRMENTS AND FUNCTIONAL LIMITATIONS, AND TO IDENTIFY EFFECTIVE TREATMENT RESPONSES THAT INCORPORATE PERSONALIZED PROTOCOLS TO OPTIMIZE FUNCTIONAL RECOVERY. THE REHABILOMICS FRAMEWORK IS A TRANSLATIONAL MODEL THAT PROVIDES AN "-OMICS" OVERLAY TO THE SCIENTIFIC STUDY OF REHABILITATION PROCESSES AND MULTIDIMENSIONAL OUTCOMES. REHABILOMICS RESEARCH PROVIDES NOVEL OPPORTUNITIES TO EVALUATE THE NEUROBIOLOGY OF COMPLEX INJURY OR CHRONIC DISEASE AND CAN BE USED TO EXAMINE METHODS AND TREATMENTS FOR PERSON-CENTERED CARE AMONG POPULATIONS WITH DISABILITIES. EXEMPLARS FOR APPLICATION IN SCI AND OTHER NEUROREHABILITATION POPULATIONS ARE DISCUSSED. 2014 17 1026 40 CIRCULATING MIRNAS EXPRESSION IN MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME. MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) IS A COMPLEX MULTIFACTORIAL DISEASE THAT CAUSES INCREASING MORBIDITY WORLDWIDE, AND MANY INDIVIDUALS WITH ME/CFS SYMPTOMS REMAIN UNDIAGNOSED DUE TO THE LACK OF DIAGNOSTIC BIOMARKERS. ITS ETIOLOGY IS STILL UNKNOWN, BUT INCREASING EVIDENCE SUPPORTS A ROLE OF HERPESVIRUSES (INCLUDING HHV-6A AND HHV-6B) AS POTENTIAL TRIGGERS. INTERESTINGLY, THE INFECTION BY THESE VIRUSES HAS BEEN REPORTED TO IMPACT THE EXPRESSION OF MICRORNAS (MIRNAS), SHORT NON-CODING RNA SEQUENCES WHICH HAVE BEEN SUGGESTED TO BE EPIGENETIC FACTORS MODULATING ME/CFS PATHOGENIC MECHANISMS. NOTABLY, THE PRESENCE OF CIRCULATING MIRNAS IN PLASMA HAS RAISED THE POSSIBILITY TO USE THEM AS VALUABLE BIOMARKERS FOR DISTINGUISHING ME/CFS PATIENTS FROM HEALTHY CONTROLS. THUS, THIS STUDY AIMED AT DETERMINING THE ROLE OF EIGHT MIRNAS, WHICH WERE SELECTED FOR THEIR PREVIOUS ASSOCIATION WITH ME/CFS, AS POTENTIAL CIRCULATING BIOMARKERS OF THE DISEASE. THEIR PRESENCE WAS QUANTITATIVELY EVALUATED IN PLASMA FROM 40 ME/CFS PATIENTS AND 20 HEALTHY CONTROLS BY SPECIFIC TAQMAN ASSAYS, AND THE RESULTS SHOWED THAT SIX OUT OF THE EIGHT OF THE SELECTED MIRNAS WERE DIFFERENTLY EXPRESSED IN PATIENTS COMPARED TO CONTROLS; MORE SPECIFICALLY, FIVE MIRNAS WERE SIGNIFICANTLY UPREGULATED (MIR-127-3P, MIR-142-5P, MIR-143-3P, MIR-150-5P, AND MIR-448), AND ONE WAS DOWNMODULATED (MIR-140-5P). MIRNA LEVELS DIRECTLY CORRELATED WITH DISEASE SEVERITY, WHEREAS NO SIGNIFICANT CORRELATIONS WERE OBSERVED WITH THE PLASMA LEVELS OF SEVEN PRO-INFLAMMATORY CYTOKINES OR WITH THE PRESENCE/LOAD OF HHV-6A/6B GENOME, AS JUDGED BY SPECIFIC PCR AMPLIFICATION. THE RESULTS MAY OPEN THE WAY FOR FURTHER VALIDATION OF MIRNAS AS NEW POTENTIAL BIOMARKERS IN ME/CFS AND INCREASE THE KNOWLEDGE OF THE COMPLEX PATHWAYS INVOLVED IN THE ME/CFS DEVELOPMENT. 2023 18 3035 22 GENETICS/GENOMICS IN CHRONIC KIDNEY DISEASE--TOWARDS PERSONALIZED MEDICINE? THE PROGRESSION RATE OF CHRONIC KIDNEY DISEASE (CKD) TO ITS TERMINAL STAGE, END-STAGE RENAL DISEASE (ESRD), AND THE DEVELOPMENT AND SEVERITY OF VARIOUS COMPLICATIONS, ARE AT LEAST INDIRECTLY INFLUENCED BY GENETIC--AND EPIGENETIC--FACTORS. FOR YEARS, SCIENTISTS HAVE HELD OUT HOPE THAT THE RAPIDLY EVOLVING FIELD OF GENETICS COULD TRANSFORM MEDICAL DIAGNOSIS AND TREATMENT, MOVING BEYOND A TRIAL-AND-ERROR APPROACH TOWARDS "PERSONALIZED MEDICINE." INDEED, THERE ARE NOW SIGNS THAT THE ROLE OF GENETICS AND THE PURSUIT OF "PERSONALIZED MEDICINE" IN MEDICAL CARE WILL BE A PRIORITY FOR GOVERNMENTS DURING YEARS TO COME. BUT THE VISION OF INDIVIDUALIZED TREATMENT BASED ON A PATIENT'S GENETIC MAKEUP AND OTHER BIOLOGICAL MARKERS HAS YET TO MATERIALIZE IN THE FIELD OF CKD AND ESRD. AS THE TOXIC UREMIC ENVIRONMENT MAY RENDER CKD PATIENTS MORE SENSITIVE TO THE EFFECTS OF GENETIC VARIANTS, IT IS LIKELY THAT GENETIC FACTORS COULD BE OF SPECIAL IMPORTANCE IN THIS HIGH-RISK POPULATION. THEREFORE, OUTCOME IN THE CKD POPULATION MAY BE IMPROVED BY ESTABLISHING INDIVIDUAL GENETIC/EPIGENETIC PROFILES, THUS ENABLING PHYSICIANS TO DESIGN AN INDIVIDUALIZED THERAPEUTIC STRATEGY. PERSONALIZED MEDICINE BASED ON A MORE INDIVIDUALIZED THERAPY COULD BE APPLIED IN, FOR EXAMPLE, PHARMACOTHERAPY (CYP GENES), DIALYSIS THERAPY, AND NUTRITIONAL AND LIFESTYLE MODIFICATIONS. 2009 19 2881 31 FUTURE PERSPECTIVES OF PERSONALIZED WEIGHT LOSS INTERVENTIONS BASED ON NUTRIGENETIC, EPIGENETIC, AND METAGENOMIC DATA. AS OBESITY HAS BECOME A MAJOR GLOBAL PUBLIC HEALTH CHALLENGE, A LARGE NUMBER OF STUDIES HAVE ANALYZED DIFFERENT STRATEGIES AIMED AT INDUCING A NEGATIVE ENERGY BALANCE AND, CONSEQUENTLY, BODY WEIGHT LOSS. HOWEVER, MOST EXISTING WEIGHT LOSS PROGRAMS ARE GENERALLY UNSUCCESSFUL, SO SEVERAL INTERVENTIONS HAVE BEEN CARRIED OUT TO IDENTIFY PHYSIOLOGIC AND BEHAVIORAL FACTORS CONCERNING THIS VARIABILITY IN ORDER TO IMPLEMENT MORE PERSONALIZED TREATMENT. NOWADAYS, AN INDIVIDUALIZED APPROACH IS BEING PROPOSED THROUGH SO-CALLED PERSONALIZED NUTRITION, WHEREBY NOT ONLY THE PHENOTYPE BUT ALSO THE GENOTYPE IS USED FOR CUSTOMIZED NUTRITION TREATMENT. REGARDING BODY WEIGHT REGULATION, APPROXIMATELY 70 POLYMORPHISMS HAVE BEEN IDENTIFIED IN OR NEAR GENES RELATED TO ENERGY EXPENDITURE, APPETITE, ADIPOGENESIS, INSULIN RESISTANCE, AND LIPID METABOLISM. ALTHOUGH PERSONALIZED NUTRITION REFERS MAINLY TO GENETIC MAKEUP, RECENT ADVANCES IN THE INVESTIGATION OF THE EPIGENOME AND THE MICROBIOME OPEN THE DOOR TO IMPLEMENT MORE PERSONALIZED RECOMMENDATIONS FOR BODY WEIGHT MANAGEMENT. IN THIS CONTEXT, RECENT STUDIES HAVE DEMONSTRATED THE EXISTENCE OF SEVERAL EPIGENETIC MARKERS THAT MAY MODIFY GENE EXPRESSION AND COULD BE INVOLVED IN THE OUTCOME OF WEIGHT LOSS INTERVENTIONS. MOREOVER, DIFFERENT STUDIES HAVE SHOWN THAT DIETARY INTERVENTIONS COULD AFFECT THE COMPOSITION OF GUT MICROBIOTA AND HAVE AN IMPACT ON BODY WEIGHT. THE INTEGRATION OF NUTRIGENETIC, EPIGENETIC, AND METAGENOMIC DATA MAY LEAD TO THE DESIGN OF MORE PERSONALIZED DIETARY TREATMENTS TO PREVENT CHRONIC DISEASES AND TO OPTIMIZE THE INDIVIDUAL'S RESPONSE TO DIETARY INTERVENTIONS. 2015 20 5163 25 PRECISION/PERSONALIZED MEDICINE IN ALLERGIC DISEASES AND ASTHMA. LIKE MANY OTHER CHRONIC DISEASES, EVERY ALLERGIC PATIENT HAS DIFFERENT CHARACTERISTICS BASED ON CLINICAL COURSE, TREATMENT RESPONSIVENESS AND DISEASE OUTCOMES, WHICH ARE ASSOCIATED WITH THE GENETIC AND EPIGENETIC CONTROL OF MOLECULAR MECHANISMS AND ENVIRONMENT. THIS VARIABILITY NECESSITATES THE ESTABLISHMENT OF PATIENT-TAILORED AND PRECISION APPROACHES IN HANDLING ALLERGIC DISORDERS. BETTER UNDERSTANDING OF THE UNDERLYING PATHOPHYSIOLOGICAL MECHANISMS FOR THE DEVELOPMENT OF ALLERGIC DISORDERS WILL PROVIDE MORE RATIONALE STRATEGIES BASED ON INDIVIDUAL CASES IN CONTROLLING AND TREATING THESE DISORDERS. ENDOTYPING, PHENOTYPING, GENOTYPING AND THERATYPING, AND BIOMARKERS ARE KEYWORDS IN THIS AREA AND HAVE BEEN GAINING LOTS OF ATTENTION IN THE FIELD OF PRECISION MEDICINE, WHICH AIMS TO REVOLUTIONIZE PATIENT CARE AND DEVELOP BETTER PREVENTION AND TREATMENT STRATEGIES. IN ADDITION, PRECISION HEALTH IS A NEW CONCEPT THAT BRINGS PRECISE APPROACHES TO THE SCENE FOR BEING HEALTHY AND PREVENTION OF ALLERGIC DISEASE AND ASTHMA. THE SPECIALTY OF ALLERGY HAS A LEADING ROLE IN THE FIELD, BECAUSE ALLERGEN-SPECIFIC IMMUNOTHERAPY STARTED 105 YEARS AGO, AND IS HISTORICALLY A LEADING PERSONALIZED/PRECISION MEDICINE APPROACH IN ALL MEDICINE DISCIPLINES PROVIDING THE POSSIBILITY OF CURE IN AN INDIVIDUALIZED MANNER INSTEAD OF CONVENTIONAL SYMPTOMATIC TREATMENTS. 2018